Axovant Gene Therapies Ltd. (AXGT) shares are trading at higher $3.64 and the avg recommendation for the stock is Strong Buy.
To add more color to this target, the company’s high over the last year is $8.08 and the low is $1.41. Over the last 52 weeks, AXGT is down -51.47% while the S&P 500 is up 13.33%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, AXGT reported a profit of $0.8 million. Axovant Gene Therapies Ltd. also saw revenues increase to $9.83 million. In addition, AXGT has free cash flow of -$13.52 million as of 06-2020. The company’s EBITDA came in at -$9.34 million which compares well with its peers.
AXGT Return on Equity (ROE) is -149.50%, and its Return on Assets is -75.10%. All told, it is clear that, AXGT needs to be on your watchlist.
Find out when AXGT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. AXGT has a short ratio of 0.75 and outstanding shares of 43.29M.
AXGT has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 0.55 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -1.96. Axovant Gene Therapies Ltd. AXGT also noted assets of $71.04 million at the end of the last quarter. Investors should also keep an eye on sector updates as AXGT has historically followed its peers on positive news.
All told, Axovant Gene Therapies Ltd. AXGT has strung together solid data and demonstrated underlying fundamentals. At its current valuation, AXGT represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Axovant Gene Therapies Ltd. AXGT is now commanding a market cap of 154.15M and a float of 23.26M. AXGT is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of AXGT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in AXGT, either long or short, and we have not been compensated for this article.